Reset Pharmaceutical News Today

Company may now initiate Phase 2b trial for treatment of demoralization syndrome in patients with cancerNEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health conditions related to life-altering diseases, today announces that the Company has received a Safe to Proceed notification from the U.S. Food and Drug Administration (FDA) regarding its Invest

EQS-News: Reset Pharmaceuticals, Inc. / Key word(s): Personnel Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer 05.01.2023 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement.  Reset Pharmaceuticals Appoints Innes Meldrum as...

EQS-News: Reset Pharmaceuticals, Inc. / Key word(s): Personnel Reset Pharmaceuticals announces appointment of neuroscience industry leader Lisa Deschamps to the Board of Directors 02.11.2022 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement.  Reset Pharmaceut...

This randomized clinical trial evaluates the combination of psychotherapy with psilocybin vs active placebo in patients with alcohol use disorder.

Published: Jul 07, 2021 By Alex Keown Collaborations are part of the life’s blood of clinical development as biopharma and life sciences companies partner and pool resources to develop novel therapies and treatments for a myriad of diseases.  This morning, multiple companies announced clinical and strategic collaborations.  PureTech Health to Harness BeiGene’s Checkpoint Inhibitor Boston-based PureTech Health plc and forged an alliance to assess the combination of BeiGene’s ex...